Arrowhead Pharmaceuticals Corp (NASDAQ: ARWR) reported Q2 EPS of $0.24, $0.05 better than the analyst estimate of $0.19. Revenue for the quarter came in at $48.15 million versus the consensus estimate of $42.99 million.

For earnings history and earnings-related data on Arrowhead Pharmaceuticals Corp (ARWR) click here.